Exposure to anti-ERBB2 agents during pregnancy (n = 328) was significantly associated with an overreporting of oligohydramnios, congenital respiratory tract disorders, and neonatal kidney failure relative to other anticancer drugs (n = 3230). Here, ERBB2 is linked to oligohydramnios.